TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01055379
Drug: Rasagiline
Normalized name: Rasagiline
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mg/day for 12 weeks; orally
Study: NCT01287338
Drug: Olopatadine
Normalized name: Olopatadine
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: low dose
Study: NCT01287338
Drug: Olopatadine
Normalized name: Olopatadine
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: high dose
Study: NCT00045695
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PS-341 bolus intravenous injection twice weekly\* for 2 out of every 3 weeks
Study: NCT04370236
Drug: INB03
Normalized name: Infliximab-abda
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive up to two once per week subcutaneous injections of 1mg/kg INB03
Study: NCT02666846
Drug: Methyl-salicylate / Menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02537444
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02537444
Drug: acalabrutinib and pembrolizumab combination
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04437108
Drug: Solifenacin
Normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients will be treated by antimuscarinics (solifenacin) which are considered as the conventional treatment of storage symptoms after prostatectomy.
Study: NCT00480441
Drug: Dronabinol
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg capsules taken 4 times daily for 2 weeks and then tapered over 1 week
Study: NCT00463151
Drug: rebamipide
Normalized name: Rebamipide
DrugBank: Rebamipide (DB11656)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 0, 60, 150, 300mg of rebamipide per day for 6 weeks into colon
Study: NCT04003974
Drug: Losmapimod oral tablet
Normalized name: Losmapimod
DrugBank: Losmapimod (DB12270)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losmapimod will be administered with food when possible.
Study: NCT04038099
Drug: Water-Based Vaginal Lubricant
Normalized name: benzoyl peroxide
DrugBank: Water (DB09145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5cc water based jelly applied intraurethral
Study: NCT04038099
Drug: lidocaine topical
Normalized name: lidocaine topical
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5cc 2% lidocaine jelly applied intraurethral
Study: NCT00678184
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg atorvastatin on two following days each
Study: NCT02697292
Drug: Intravenous Immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAMUNEX-C is a clear a ready-to-use sterile solution of human immune globulin protein for intravenous administration. Dose will be determined based on ideal wt. with not to exceed 80 grams. Subjects will receive 0.5g/kg daily for 1 day \[week 1 day 1\], then will receive 1g/kg not exceeding 80 grams daily for 1 day \[week 1 day 2\]. Then once every 2 weeks subjects will receive 0.6g/kg IVIG for 4 weeks \[week 3 and 5\] for 2 infusions.
Study: NCT01349751
Drug: isobaric levobupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.42% either isobaric levobupivacaine 3 ml spinal injection once
Study: NCT03226821
Drug: Tesamorelin
Normalized name: Tesamorelin
DrugBank: Tesamorelin (DB08869)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be treated with tesamorelin 2 mg by subcutaneous injection daily
Study: NCT00454441
Drug: MF101
Normalized name: MF101
DrugBank: MF101 (DB05052)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01349751
Drug: hyperbaric levobupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.42% hyperbaric levobupivacaine 3 ml spinal injection once
Study: NCT02026310
Drug: glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: on the basis of metformin and glargine, glimepiride is added; with the maximun dose of glimepiride, if the targeted FPG is not reached, glargine dose will be increased.
Study: NCT02026310
Drug: glargine and metformin
Normalized name: insulin glargine and lixisenatide
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02251353
Drug: systemic treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic therapy
Study: NCT03991104
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin (3 levels for phase I: 110 mg/m², 120 mg/m² and 130 mg/m²) is administered as a 2 h intravenous infusion in 500 mL of 5% glucose on day 1 and day 29 during the treatment course.
Study: NCT03991104
Drug: S-1 capsule
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Patients received a fixed dose of S-1 with a dose of 80 mg/m2/d twice daily for 2 weeks, every 4 weeks.
Study: NCT00696293
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duloxetine up to 120 mg/day + Clinical Management
Study: NCT01220440
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate:10mg x 3 for one week
Study: NCT01220440
Drug: Dextroamphetamine
Normalized name: Dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine: 5mg x 2 for one week, 10mg x 2 for one week
Study: NCT00209729
Drug: Taxotere
Normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: X mg/m2, IV (in the vein) on day 1 and 15 of each 28 day cycle.
Study: NCT00209729
Drug: TS-1
Normalized name: CTS-1027
DrugBank: Gimeracil (DB09257)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Day 1-14, P.O. everyday
Study: NCT04142125
Drug: Rivaroxaban 2.5 Mg Oral Tablet bid
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pts will receive rivaroxaban + aspirin
Study: NCT04142125
Drug: Acetylsalicyclic acid 81 mg tablet qd
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pts will receive ASA
Study: NCT01582243
Drug: Vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin 50 mg plus metformin 500 mg as Single Pill combination (SPC)
Study: NCT00191685
Drug: duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04002089
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.3%, 13.3 mg/mL
Study: NCT01517022
Drug: nicotine replacement therapy
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nicotine replacement therapy 2mg for patients cessation arm for period of 6 weeks
Study: NCT02883543
Drug: icotinib
Normalized name: icotinib
DrugBank: Icotinib (DB11737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icotinib is orally administered three times per day.
Study: NCT01627236
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: methylprednisolone 1mg/kg intravenous drip qd，for 3 days glucocorticoid
Study: NCT03033914
Drug: Bleomycin
Normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bleomycin: 10 units/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
Study: NCT03033914
Drug: vinblastine
Normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinblastine: 6 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
Study: NCT03033914
Drug: dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine (DTIC): 375 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
Study: NCT02711462
Drug: PF-06687234
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06687234 will be administered via the SC or the IV route and in either single dose or multiple doses
Study: NCT01186770
Drug: Methylnaltrexone
Normalized name: Methylnaltrexone
DrugBank: Methylnaltrexone (DB06800)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.
Study: NCT03033914
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nivolumab 240mg q14 days
Study: NCT01222247
Drug: Betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The active study drug, betamethasone. 3 mg per ml betamethasone sodium phosphate 3 mg per milliliter betamethasone acetate The first dose of study drug medication will be administered at randomization as 2 ml injection; the next dose of 2 ml will be administered 24 hours later.
Study: NCT01827280
Drug: Vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin 50mg/pill will be administered at 10 AM and at 6 PM also for 30 days.
Study: NCT04460079
Drug: Peg-filgrastim
Normalized name: peg-filgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PegaGen® was injected as a single subcutaneous dose after completion of cytotoxic chemotherapy
Study: NCT03176134
Drug: Tedizolid phosphate
Normalized name: Tedizolid Phosphate
DrugBank: Tedizolid phosphate (DB09042)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tedizolid phosphate IV solution or oral suspension
Study: NCT02518932
Drug: Last 5 amino acids of GLP-1
Normalized name: 4-Amino-5-hexenoic acid
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To examine insulinomimetic properties of LVKGR
Study: NCT02522117
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients were assigned to two groups; one of them received oral atorvastatin (study group), and the other homologated placebo (control group) for 4 weeks before transplant. Then IL2, IL6, TNFalpha and HLA levels were assessed in the recipient's kidney graft by visual analog scale at prior reperfusion, and after 3 and 12 months.
Study: NCT00572689
Drug: Exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 microgram injected sub-cutaneously once
Study: NCT00550199
Drug: LBH589, Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase I dose escalation: LBH589 will be administered orally twice weekly. Gemcitabine will be administered intravenously over 30 minutes on days 1, 8, and 15 every 28 days.
Study: NCT04057833
Drug: E-CEL UVEC
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local implantation of E-CEL UVEC cells at the supraspinatus tendon repair site
Study: NCT03217292
Drug: IV patient-controlled analgesia (PCA) tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02572453
Drug: Onalespib
Normalized name: Onalespib
DrugBank: Onalespib (DB06306)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02906683
Drug: TAS-303
Normalized name: TAS-303
DrugBank: TAS-303 (DB18808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration for 8 weeks, once daily.
Study: NCT04339218
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be prescribed and administered at the dose recommended by market authorization.
Study: NCT04339218
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed will be prescribed and administered at the dose recommended by market authorization.
Study: NCT04339218
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be prescribed and administered at the dose recommended by market authorization.
Study: NCT02965924
Drug: Phenylephrine 2.5%
Normalized name: PHENYLEPHRINE 2.5%/TROPICAMIDE 1% SOLN,OPH
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Instilling phenylephrine 2.5% eye drop
Study: NCT04212169
Drug: MEDI3506
Normalized name: MEDI3506
DrugBank: MEDI3506 (DB16473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple doses
Study: NCT00511472
Drug: LANTUS insulin
Normalized name: insulin glargine Injectable Solution [Lantus]
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LANTUS insulin dose will be similar to participant's previous dose of immediate or long-acting insulin
Study: NCT05545462
Drug: Doxycyclin
Normalized name: Doxycyclin
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: THE USE OF DOXYCYCLIN POWDER IN THE TREATMENT OF UMBILICAL GRANULOMA
Study: NCT02146456
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02778711
Drug: secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: anti-IL-17
Study: NCT04552197
Drug: JNJ-64251330
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64251330 tablet will be administered orally.
Study: NCT04552197
Drug: Tofacitinib
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tofacitinib tablets will be administered orally.
Study: NCT02151721
Drug: Vorinostat, gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat 200, 300, or 400 mg orally once daily on days 1-7 with washout on days 8-14 plus gefitinib 250 mg orally once daily on days 1-14
Study: NCT00572390
Drug: oestrogen
Normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclic oestrogen substitution therapy
Study: NCT03618654
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT00290043
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00003686
Drug: pilocarpine hydrochloride
Normalized name: Pilocarpine Hydrochloride
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine 5 mg po qid x 4 weeks
Study: NCT00243243
Drug: Recombinant Factor VIIa
Normalized name: Human recombinant factor VIIa variant (P10Q, K32E, T106N, V253N), desialylated
DrugBank: CT-001 (DB18284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion of Factor VIIa
Study: NCT01556217
Drug: JNJ-39393406
Normalized name: JNJ-39393406
DrugBank: JNJ-39393406 (DB11867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type= exact number, Unit= mg, Number= 200, Form= oral suspension, Route= oral administration. Oral suspension to be taken once with 240 mL (8 ounces of water) between 8:00 AM and 10:30 AM.
Study: NCT00454298
Drug: AGG-523 (Aggrecanase Inhibitor)
Normalized name: Fibrinolysis inhibitor
DrugBank: AGG-523 (DB15460)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00562406
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravitreal injection of 0.5 mg ranibizumab after randomisation, at week 4 and 8
Study: NCT03272126
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin D given as bolus versus daily dosing
Study: NCT00565539
Drug: PEGylated recombinant interleukin 29 (PEG-rIL-29)
Normalized name: Recombinant interleukin-11
DrugBank: Oprelvekin (DB00038)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous administration either weekly or every other week
Study: NCT00000575
Drug: Nedocromil
Normalized name: NEDOCROMIL
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Four 2 mg puffs bid + two 90 Og puffs albuterol prn
Study: NCT00000575
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Two 100 Og puffs bid + two 90 Og puffs albuterol prn.
Study: NCT05198141
Drug: Letrozole tablets
Normalized name: Letrozole Tablets
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GI: Patients who were undergoing laparoscopic salpingectomy GII: patients who medically treated with 5 mg d-1 of letrozole using two tablets (2.5 mg of Femara) every day for 10 d GIII patients who medically treated with 10 mg d-1 of letrozole using four tablets (2.5 mg of Femara) every day for 10 d (group III)
Study: NCT00282217
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01932385
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02215382
Drug: sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sugammadex 2 mg/kg
Study: NCT01426815
Drug: Golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The prefilled syringe with golimumab 50mg (Simponi ®) will be administrated subcutaneously every 4 weeks during a study period of 48 weeks.
Study: NCT02990728
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The enrolled patient is allocated to either LNG-IUS only or LNG-IUS + metformin by central randomization with study site allocation. A 90-100 days of continuous treatment before first histologic assessment of treatment response is required. The patient will receive endometrial curettage or hysteroscopic evaluation and resection of suspected lesion after 90-100 days of treatment. Patients with good response to assigned treatment will continue the treatment for another 90-100 days and second histologic assessment will be performed. Patients with poor response to assigned treatment at first assessment will receive additive oral progestin therapy, along with the assigned regimen(s) as, Oral progestin, either medroxyprogesterone acetate 500 mg daily or oral megestrol acetate 160 mg daily After a total of at least 6 months treatment period, the patient with good response at first assessment is suggested to keep the Mirena for maintenance until plan to get pregnant
Study: NCT02215382
Drug: neostigmine+atropine
Normalized name: atropine / neostigmine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: neostigmine 0,05 mg/kg + atropine 0,025 mg/kg
Study: NCT03876925
Drug: CT053PTSA
Normalized name: Ct053ptsa free base
DrugBank: Ningetinib (DB16256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will received oral CT053PTSA once daily until disease progression or intolerable toxicity or subject's withdrawal from treatment ,each cycle is defined as 28 days
Study: NCT00889018
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 560 mg/m2 (18.6 mg/kg for children £36 months old). .
Study: NCT00889018
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 750 mg/m2 (25 mg/kg for children £36 months old).
Study: NCT00942136
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 40 mg once a day for 5 days. Omeprazole is approved by the FDA currently to reduce stomach acid, treat stomach ulcers, and gastroesophageal reflux disease.
Study: NCT01658826
Drug: Valacyclovir
Normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg oral administration
Study: NCT01584713
Drug: Adipose-derived stem cells without expanded
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
Study: NCT03372486
Drug: Bupivacaine plus naloxone
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received 20 mL bupivacaine 0.5% plus 100 ng naloxone (1ml) in 2ml saline.(naloxone ampoule 0.4mg will dilute in 400ml of saline then 1ml of it will dilute in 10 ml saline, so each ml will have 100ng naloxone)
Study: NCT02739373
Drug: BMS-986189
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04290169
Drug: IncobotulinumtoxinA
Normalized name: incobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: IncobotulinumtoxinA will be injected in upper extremities according to recommended guidelines. Two methods will be used in the study: auditive electromyography (EMG) and ultrasound guided injection technique. The decision process of which muscles to inject will be based on information obtained through examination of hand function, the presence of increased muscle tone during the clinical examination as well as a positive response from auditive EMG
Study: NCT02881957
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00265746
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00169299
Drug: Black cohosh
Normalized name: black cohosh
DrugBank: Black cohosh (DB13975)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00169299
Drug: Multibotanical preparation
Normalized name: cranberry preparation
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no